Rectum and Bladder Toxicity in Postoperative Prostate Bed Irradiation: Dose-Volume Parameters Analysis
- PMID: 38001594
- PMCID: PMC10670737
- DOI: 10.3390/cancers15225334
Rectum and Bladder Toxicity in Postoperative Prostate Bed Irradiation: Dose-Volume Parameters Analysis
Abstract
Although prostate cancer treatment is increasingly effective, its toxicities pose a major concern. The aim of our study was to assess the rate of adverse events (AEs) and the prognostic value of dose-volume histogram (DVH) parameters for the occurrence of treatment toxicity in patients treated with post-prostatectomy prostate bed radiotherapy (RT). The AEs were scored according to the CTCAE v.5.0. The rectum and bladder were contoured according to the RTOG Guidelines. The DVH parameters were assessed using data exported from the ECLIPSE treatment-planning system. Genitourinary (GU) and gastrointestinal (GI) toxicity were analysed using consecutive dose thresholds for the percentage of an organ at risk (OAR) receiving a given dose and the QUANTEC dose constraints. A total of 213 patients were included in the final analysis. Acute grade 2 or higher (≥G2) GU AEs occurred in 18.7% and late in 21.3% of patients. Acute ≥G2 GI toxicity occurred in 11.7% and late ≥G2 in 11.2% of the patients. Five patients experienced grade 4 AEs. The most common adverse effects were diarrhoea, proctitis, cystitis, and dysuria. The most significant predictors of acute ≥G2 GI toxicity were rectum V47 and V46 (p < 0.001 and p < 0.001) and rectum wall V46 (p = 0.001), whereas the most significant predictors of late ≥G2 GI AEs were rectum wall V47 and V48 (p = 0.019 and p = 0.021). None of the bladder or bladder wall parameters was significantly associated with the risk of acute toxicity. The minimum doses to bladder wall (p = 0.004) and bladder (p = 0.005) were the most significant predictors of late ≥G2 GU toxicity. Postoperative radiotherapy is associated with a clinically relevant risk of AEs, which is associated with DVH parameters, and remains even in patients who fulfil commonly accepted dose constraints. Considering the lack of survival benefit of postoperative adjuvant RT, our results support delaying treatment through an early salvage approach to avoid or defer toxicity.
Keywords: QUANTEC; adjuvant radiotherapy; adverse events; dose constraints; dose–volume histogram; postoperative irradiation; prostate cancer; salvage radiotherapy.
Conflict of interest statement
The authors declare no conflict of interest.
Figures
Similar articles
-
Late toxicity after post-prostatectomy intensity modulated radiation therapy: Evaluating normal-tissue sparing guidelines.Adv Radiat Oncol. 2018 May 8;3(3):339-345. doi: 10.1016/j.adro.2018.04.009. eCollection 2018 Jul-Sep. Adv Radiat Oncol. 2018. PMID: 30202803 Free PMC article.
-
Volume and hormonal effects for acute side effects of rectum and bladder during conformal radiotherapy for prostate cancer.Int J Radiat Oncol Biol Phys. 2005 Nov 15;63(4):1142-52. doi: 10.1016/j.ijrobp.2005.03.060. Epub 2005 Jun 4. Int J Radiat Oncol Biol Phys. 2005. PMID: 15939547 Clinical Trial.
-
Late toxicity after intensity-modulated radiation therapy for localized prostate cancer: an exploration of dose-volume histogram parameters to limit genitourinary and gastrointestinal toxicity.Int J Radiat Oncol Biol Phys. 2012 Jan 1;82(1):235-41. doi: 10.1016/j.ijrobp.2010.09.058. Epub 2010 Dec 14. Int J Radiat Oncol Biol Phys. 2012. PMID: 21163587
-
Dose-volume analysis of predictors for chronic rectal toxicity after treatment of prostate cancer with adaptive image-guided radiotherapy.Int J Radiat Oncol Biol Phys. 2005 Aug 1;62(5):1297-308. doi: 10.1016/j.ijrobp.2004.12.052. Int J Radiat Oncol Biol Phys. 2005. PMID: 16029785 Review.
-
Pelvic Complications After Prostate Cancer Radiation Therapy and Their Management: An International Collaborative Narrative Review.Eur Urol. 2019 Mar;75(3):464-476. doi: 10.1016/j.eururo.2018.12.003. Epub 2018 Dec 17. Eur Urol. 2019. PMID: 30573316
Cited by
-
A Multicenter Machine Learning-Based Predictive Model of Acute Toxicity in Prostate Cancer Patients Undergoing Salvage Radiotherapy (ICAROS Study).Cancers (Basel). 2025 Jun 25;17(13):2142. doi: 10.3390/cancers17132142. Cancers (Basel). 2025. PMID: 40647440 Free PMC article.
-
Long-term Outcomes of Salvage Radiotherapy Using TomoTherapy With Image-guided Radiotherapy for Postoperative Prostate Cancer Patients.Cancer Diagn Progn. 2025 Mar 3;5(2):189-197. doi: 10.21873/cdp.10429. eCollection 2025 Mar-Apr. Cancer Diagn Progn. 2025. PMID: 40034950 Free PMC article.
References
-
- Kneebone A., Fraser-Browne C., Duchesne G.M., Fisher R., Frydenberg M., Herschtal A., Williams S.G., Brown C., Delprado W., Haworth A., et al. Adjuvant Radiotherapy versus Early Salvage Radiotherapy Following Radical Prostatectomy (TROG 08.03/ANZUP RAVES): A Randomised, Controlled, Phase 3, Non-Inferiority Trial. Lancet Oncol. 2020;21:1331–1340. doi: 10.1016/S1470-2045(20)30456-3. - DOI - PubMed
-
- Parker C.C., Clarke N.W., Cook A.D., Kynaston H.G., Petersen P.M., Catton C., Cross W., Logue J., Parulekar W., Payne H., et al. Timing of Radiotherapy after Radical Prostatectomy (RADICALS-RT): A Randomised, Controlled Phase 3 Trial. Lancet. 2020;396:1413–1421. doi: 10.1016/S0140-6736(20)31553-1. - DOI - PMC - PubMed
-
- Sargos P., Chabaud S., Latorzeff I., Magné N., Benyoucef A., Supiot S., Pasquier D., Abdiche M.S., Gilliot O., Graff-Cailleaud P., et al. Adjuvant Radiotherapy versus Early Salvage Radiotherapy plus Short-Term Androgen Deprivation Therapy in Men with Localised Prostate Cancer after Radical Prostatectomy (GETUG-AFU 17): A Randomised, Phase 3 Trial. Lancet Oncol. 2020;21:1341–1352. doi: 10.1016/S1470-2045(20)30454-X. - DOI - PubMed
-
- Prostate Cancer—INTRODUCTION—Uroweb. [(accessed on 7 November 2023)]. Available online: https://uroweb.org/guidelines/prostate-cancer/chapter/introduction.
-
- Gay H.A., Barthold H.J., O’Meara E., Bosch W.R., El Naqa I., Al-Lozi R., Rosenthal S.A., Lawton C., Lee W.R., Sandler H., et al. Pelvic Normal Tissue Contouring Guidelines for Radiation Therapy: A Radiation Therapy Oncology Group Consensus Panel Atlas. Int. J. Radiat. Oncol. Biol. Phys. 2012;83:e353–e362. doi: 10.1016/j.ijrobp.2012.01.023. - DOI - PMC - PubMed
LinkOut - more resources
Full Text Sources